We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In Rare Clinical Superiority Determination, Jazz’s Narcolepsy Med Earns Seven-Year Exclusivity
In Rare Clinical Superiority Determination, Jazz’s Narcolepsy Med Earns Seven-Year Exclusivity
Jazz Pharmaceuticals’ Xywav (calcium, magnesium, potassium and sodium oxybates) has earned the FDA’s coveted seven-year orphan drug exclusivity for treating cataplexy or excessive daytime sleepiness in narcolepsy patients age seven years and up. The exclusivity is a big win for the company, which already has a narcolepsy cash cow on the market.